Terms: = Ovarian cancer AND CTNNB1, P35222, 1499, ENSG00000168036, CTNNB AND Prognosis
31 results:
1. Complexity of the Genetic Background of Oncogenesis in ovarian cancer-Genetic Instability and Clinical Implications.
Murawski M; Jagodziński A; Bielawska-Pohl A; Klimczak A
Cells; 2024 Feb; 13(4):. PubMed ID: 38391958
[TBL] [Abstract] [Full Text] [Related]
2. Genomic and Molecular Characteristics of ovarian Carcinosarcoma.
Ramphal K; Hadfield MJ; Bandera CM; Hart J; Dizon DS
Am J Clin Oncol; 2023 Dec; 46(12):572-576. PubMed ID: 37986208
[TBL] [Abstract] [Full Text] [Related]
3. HDACs alters negatively to the tumor immune microenvironment in gynecologic cancers.
Yan M; Cao H; Tao K; Xiao B; Chu Y; Ma D; Huang X; Han Y; Ji T
Gene; 2023 Nov; 885():147704. PubMed ID: 37572797
[TBL] [Abstract] [Full Text] [Related]
4. HER2+ endometrioid endometrial cancer possesses distinct molecular and immunologic features associated with a more active immune microenvironment and worse prognosis.
Bruce SF; Wu S; Ribeiro JR; Farrell A; Oberley MJ; Winer I; Erickson BK; Klc T; Jones NL; Thaker PH; Powell MA
Gynecol Oncol; 2023 May; 172():98-105. PubMed ID: 37003074
[TBL] [Abstract] [Full Text] [Related]
5. Potential prognostic role of somatic mutations in a set of cancer susceptibility genes in ovarian carcinoma: A follow-up multicentric study from Pakistan.
Masood A; Sarfaraz R; Zaki S; Shami A; Khaliq S; Naseem N
Cancer Biomark; 2023; 36(3):207-219. PubMed ID: 36776043
[TBL] [Abstract] [Full Text] [Related]
6. Diagnostic accuracy of mutational analysis along the Müllerian tract to detect ovarian cancer.
van Bommel MHD; Pijnenborg JMA; van der Putten LJM; Bulten J; Snijders MPLM; Küsters-Vandevelde HVN; Sweegers S; Vos MC; Ligtenberg MJL; Eijkelenboom A; de Hullu JA; Reijnen C
Int J Gynecol Cancer; 2022 Dec; 32(12):1568-1575. PubMed ID: 36384753
[TBL] [Abstract] [Full Text] [Related]
7. Molecular Evidence for Epithelial Origin of Mixed ovarian Epithelial-Germ Cell Neoplasms: Report of 2 Cases and Review of Literature.
Hall KC; Post MD; Alldredge J; Aisner DL; Berning A
Int J Gynecol Pathol; 2023 Jul; 42(4):403-413. PubMed ID: 36305517
[TBL] [Abstract] [Full Text] [Related]
8. Clinical impact of genetic alterations of ctnnb1 in patients with grade 3 endometrial endometrioid carcinoma.
Kobayashi Kato M; Asami Y; Takayanagi D; Matsuda M; Shimada Y; Hiranuma K; Kuno I; Komatsu M; Hamamoto R; Matsumoto K; Ishikawa M; Kohno T; Kato T; Shiraishi K; Yoshida H
Cancer Sci; 2022 May; 113(5):1712-1721. PubMed ID: 35278272
[TBL] [Abstract] [Full Text] [Related]
9. Clinicopathologic Evaluation and Molecular Profiling of Recurrent Stage IA Endometrial Endometrioid Carcinoma: A Case-control Study.
Sharma AE; Moran A; Somasegar S; Steinhardt G; Chapel DB; Lastra RR; Lee NK; Ritterhouse LL; Bennett JA
Int J Gynecol Pathol; 2023 Jan; 42(1):26-34. PubMed ID: 35125405
[TBL] [Abstract] [Full Text] [Related]
10. A 46-Year-Old Woman with Primary Infertility and a Diagnosis of Microcystic Stromal Tumor of the Ovary Confirmed by Histology and Gene Sequencing: A Case Report and Review of the Literature.
Arafah MA; AlBreacan L; Akkour K; Alomar S
Am J Case Rep; 2021 Oct; 22():e933528. PubMed ID: 34667141
[TBL] [Abstract] [Full Text] [Related]
11. Clinicopathological features and prognostic significance of ctnnb1 mutation in low-grade, early-stage endometrial endometrioid carcinoma.
Ruz-Caracuel I; López-Janeiro Á; Heredia-Soto V; Ramón-Patino JL; Yébenes L; Berjón A; Hernández A; Gallego A; Ruiz P; Redondo A; Peláez-García A; Mendiola M; Hardisson D
Virchows Arch; 2021 Dec; 479(6):1167-1176. PubMed ID: 34420090
[TBL] [Abstract] [Full Text] [Related]
12. Vitamin D receptor upregulates lncRNA TOPORS-AS1 which inhibits the Wnt/β-catenin pathway and associates with favorable prognosis of ovarian cancer.
Fu Y; Katsaros D; Biglia N; Wang Z; Pagano I; Tius M; Tiirikainen M; Rosser C; Yang H; Yu H
Sci Rep; 2021 Apr; 11(1):7484. PubMed ID: 33820921
[TBL] [Abstract] [Full Text] [Related]
13. Molecularly Classified Uterine FIGO Grade 3 Endometrioid Carcinomas Show Distinctive Clinical Outcomes But Overlapping Morphologic Features.
Joehlin-Price A; Van Ziffle J; Hills NK; Ladwig N; Rabban JT; Garg K
Am J Surg Pathol; 2021 Mar; 45(3):421-429. PubMed ID: 33021522
[TBL] [Abstract] [Full Text] [Related]
14. ctnnb1 Mutations and Aberrant β-Catenin Expression in ovarian Endometrioid Carcinoma: Correlation With Patient Outcome.
Zyla RE; Olkhov-Mitsel E; Amemiya Y; Bassiouny D; Seth A; Djordjevic B; Nofech-Mozes S; Parra-Herran C
Am J Surg Pathol; 2021 Jan; 45(1):68-76. PubMed ID: 32769429
[TBL] [Abstract] [Full Text] [Related]
15. Clinical patterns and genomic profiling of recurrent 'ultra-low risk' endometrial cancer.
Stasenko M; Feit N; Lee SSK; Shepherd C; Soslow RA; Cadoo KA; Alektiar K; Da Silva EM; Martins Sebastião AP; Leitao MM; Gardner G; Selenica P; Abu-Rustum NR; Weigelt B; Mueller JJ
Int J Gynecol Cancer; 2020 Jun; 30(6):717-723. PubMed ID: 32376737
[TBL] [Abstract] [Full Text] [Related]
16. Identification of a Gene Panel for Endometrioid Endometrial cancer: a Possible Prognostic Value?
Malentacchi F; Turrini I; Sorbi F; Projetto E; Castiglione F; Vergoni F; Amunni G; Fambrini M; Petraglia F; Noci I; Pillozzi S
Reprod Sci; 2020 Feb; 27(2):592-598. PubMed ID: 32046431
[TBL] [Abstract] [Full Text] [Related]
17. The relationship between
Çintesun FNİ; Kerimoğlu ÖS; Çintesun E; Nergiz S; Acar H; Çelik Ç
J Obstet Gynaecol; 2020 Oct; 40(7):988-993. PubMed ID: 31790621
[TBL] [Abstract] [Full Text] [Related]
18. Multiclonality and Marked Branched Evolution of Low-Grade Endometrioid Endometrial Carcinoma.
Lazo de la Vega L; Samaha MC; Hu K; Bick NR; Siddiqui J; Hovelson DH; Liu CJ; Carter CS; Cho KR; Sciallis AP; Tomlins SA
Mol Cancer Res; 2019 Mar; 17(3):731-740. PubMed ID: 30610106
[TBL] [Abstract] [Full Text] [Related]
19. High frequency of POLE mutations in synchronous endometrial and ovarian carcinoma.
Ishikawa M; Nakayama K; Nakamura K; Ono R; Yamashita H; Ishibashi T; Minamoto T; Iida K; Razia S; Ishikawa N; Kyo S
Hum Pathol; 2019 Mar; 85():92-100. PubMed ID: 30448219
[TBL] [Abstract] [Full Text] [Related]
20. Nuclear β-catenin and CDX2 expression in ovarian endometrioid carcinoma identify patients with favourable outcome.
Wang L; Rambau PF; Kelemen LE; Anglesio MS; Leung S; Talhouk A; Köbel M
Histopathology; 2019 Feb; 74(3):452-462. PubMed ID: 30326146
[TBL] [Abstract] [Full Text] [Related]
[Next]
